|
|
News Breaks | | | | February 28, 2013 | | 16:32 EDT |  | AMRN | Amarin is making progress expanding patent protection for Vascepa
Amarin continues to make significant progress in its effort to expand patent protection for Vascepa and now has 18 patents issued or allowed with over 30 additional patent applications being prosecuted in the United States. This patent portfolio includes claims covering key elements of Vascepa's pharmaceutical composition and methods of use for the MARINE indication, ANCHOR indication and other potential uses of Vascepa. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States. Amarin's goal is to protect the commercial potential of Vascepa beyond 2030. Patent protection for Vascepa is augmented by protection provided by trade secrets, taking advantage of manufacturing barriers to entry and regulatory exclusivity | |
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 17, 2013 | | 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information | | | May 15, 2013 | | 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. | | | May 13, 2013 | | 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information | | | May 10, 2013 | | 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. | | | May 9, 2013 | | 16:18 EDT |  | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. | | | 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information | |
|
|
|
|
|
|
